News

This small interfering ribonucleic acid (RNA)[siRNA] therapy is designed to combat one of the ALS subtypes, FUS-ALS, by reducing FUS protein levels. RAG-21 leverages RNA interference (RNAi) technology

This rare genetic disease currently lacks FDA-approved treatments, making the submission a significant milestone. Plozasiran, also known as ARO-APOC3, is an investigational RNA interference (RNAi) therapeutic. It aims

Under the agreement, Kaken has secured an option to acquire commercial rights to the antibody in select Asian territories. In return, the company will fund the preclinical and

The FDA has set a target action date of 18 April 2025 for its decision. If approved, Dupixent is expected to become the first targeted CSU therapy in

This grant will aid the progression of ASHA-624 towards first-in-human clinical trials. Designed using the company’s PRISM drug design technology, it is a brain-penetrant intra-molecular glue inhibitor of

The BLA is sought for treating NSCLC patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) who have received systemic therapies previously. Concurrently, the companies have

The $0.6m (4m yuan) deal, which will facilitate Lakeside’s entry into the medical logistics sector, is set to contribute an estimated $7m in annual revenues to the integrated

ALT-B4 will be used for developing the subcutaneous formulation ENHERTU. As per the agreement, Daiichi Sankyo will gain global rights to utilise Alteogen’s ALT-B4, a human recombinant hyaluronidase

Situated in Milton Park, near Oxford, the new 30,000ft2 facility is part of NEB’s wholly-owned subsidiary network. The site is designed to offer solutions for ambient molecular biology